Profile: ChemGenex Pharmaceuticals Limited (CXSPY.PK)

ChemGenex Pharmaceuticals Limited (ChemGenex) is an integrated biopharmaceutical development company with specializes in the discovery and the development of oncology drugs. ChemGenex focuses to develop targeted medicines for the treatment of cancer by identifying and targeting the genetic components of a range of cancer types. The Company has two molecules in clinical trials and is supporting to identify and progress further pre-clinical anti-cancer compounds. The Company operates in the oncology segment and it has operations in Australia and United States.

The Company focuses on the development of therapeutic agents in cancer. As of June 30, 2009, ChemGenex had two small molecule drug candidates in human clinical trials. ChemGenex’s other development stage molecule, Quinamed, has completed phase IIa clinical trials in a range of solid cancers. The Company’s product candidate, omacetaxine mepesuccinate is an investigational small molecule agent, for the treatment of chronic myelogenous leukemia (CML) patients with the T315I point mutation who are resistant to Gleevec. The Company’s product candidate, Quinamed is in a Phase II trial for the treatment of hormone refractory prostate cancer.